Global IgA Nephropathy Treatment Market Report and Forecast 2023-2031

Global IgA Nephropathy Treatment Market Report and Forecast 2023-2031

Global IgA Nephropathy Treatment Market Outlook

The global IgA nephropathy treatment market size was valued at USD 245.8 million in 2022 and is projected to grow at a CAGR of 4.2% during the forecast period of 2023-2031 to reach a value of USD 356.0 million by 2031. The market growth can be attributed to the increasing prevalence of IgA nephropathy, growing awareness about kidney diseases, and advancements in treatment options.

Global IgA Nephropathy Treatment Market: Introduction

IgA nephropathy, also known as Berger's disease, is a kidney disorder caused by the deposition of the immunoglobulin A (IgA) antibody in the kidneys, leading to inflammation and potential kidney damage. The treatment options for IgA nephropathy include medication, dietary changes, and supportive care. The increasing prevalence of IgA nephropathy, coupled with the rising awareness about kidney diseases, is driving the demand for effective treatment options.

Advancements in medical research have led to the development of new treatment options for IgA nephropathy, including targeted therapies and novel immunosuppressive drugs. Additionally, the growing awareness about kidney diseases and the need for early diagnosis and treatment are also expected to drive market growth.

IgA Nephropathy Epidemiology

According to the National Kidney Foundation, IgA nephropathy is the most common primary glomerulonephritis worldwide, affecting an estimated 2.5 million people globally. The prevalence of IgA nephropathy varies among countries, with higher rates observed in Asia, particularly in Japan and China. The disease affects both men and women, with a higher prevalence in males.

Efforts to improve access to IgA nephropathy treatment should take into account the unique needs of different regions, as well as the underlying factors that contribute to the development of the disease, such as genetics, environmental factors, and lifestyle choices. By addressing these factors, we can work towards reducing the burden of IgA nephropathy and improving access to effective treatment.

IgA Nephropathy Treatment Market Segmentations

The market can be segmented based on diagnosis methods, treatment methods, diseases type, symptoms, age group, route of administration, treatment channel, distribution channel, end-user, and region:

Market Breakup by Diagnosis Method

• Blood Test
• Urine Test
• Kidney Biopsy
• Iothalamate Clearance Test
• Others

Market Breakup by Treatment Method

• Corticosteroid Drugs
• Immunosuppressive Drugs
• ACE inhibitors and ARBs
• Others

Market Breakup by Disease Type

• Primary IgA Nephropathy
• Secondary IgA Nephropathy

Market Breakup by Symptoms

• Haematuria
• Proteinuria
• Oedema
• Others

Market Breakup by Age Group

• Adults
• Children

Market Breakup by Route of Administration

• Oral
• Tablets/Pills
• Capsules
• Others
• Parenteral
• Intravenous
• Intramuscular
• Others
• Others

IgA Nephropathy Treatment Market Breakup by Treatment Channel

• Public
• Private

Market Breakup by Distribution Channel of Drugs

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Direct Tender
• Others

Market Breakup by End User

• Hospitals
• Clinics
• Home Healthcare
• Others

Market Breakup by Region

• North America
• United States of America
• Canada
• Europe
• United Kingdom
• Germany
• France
• Italy
• Others
• Asia Pacific
• China
• Japan
• India
• ASEAN
• Australia
• Others
• Latin America
• Brazil
• Argentina
• Mexico
• Others
• Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

IgA Nephropathy Treatment Market Analysis

The market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of IgA nephropathy, rising awareness about kidney diseases, and advancements in treatment options.

North America is currently the largest market for IgA nephropathy treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of IgA nephropathy, a well-established healthcare infrastructure, and strong investment in medical research and development. In addition, the growing adoption of new treatment options and increased awareness about kidney diseases are further driving the growth of the market in North America.

Europe is also a significant market for IgA nephropathy treatment, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of kidney diseases, and government initiatives to address kidney health concerns. Additionally, the region has a well-established healthcare system, which supports the delivery of IgA nephropathy treatment. Asia Pacific is another region that is experiencing significant growth in the IgA nephropathy treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of kidney diseases, and the growing adoption of new treatment options. In addition, government initiatives to address kidney health concerns are helping to drive the growth of the market in the region.

Key Players in the Global IgA Nephropathy Treatment Market

The report provides a detailed analysis of the key players involved in the IgA nephropathy treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

• Novartis AG
• Calliditas Therapeutics AB
• Chinook Therapeutics Inc.
• Travere Therapeutics Inc.
• Omeros Corporation
• VIFOR Pharma
• Vera Therapeutics Inc.
• Merck KGaA
• Reata Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Apellis Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co. Ltd